Alexion Pharmaceuticals (NASDAQ:ALXN) Receives New Coverage from Analysts at SunTrust Banks

Analysts at SunTrust Banks assumed coverage on shares of Alexion Pharmaceuticals (NASDAQ:ALXN) in a report released on Tuesday, The Fly reports. The firm set a “buy” rating on the biopharmaceutical company’s stock.

ALXN has been the subject of a number of other research reports. BMO Capital Markets assumed coverage on Alexion Pharmaceuticals in a research report on Thursday, September 12th. They set an “outperform” rating and a $149.00 price objective for the company. ValuEngine upgraded Alexion Pharmaceuticals from a “strong sell” rating to a “sell” rating in a research report on Wednesday, October 2nd. Piper Jaffray Companies set a $180.00 price target on Alexion Pharmaceuticals and gave the stock a “buy” rating in a research report on Friday, September 6th. Royal Bank of Canada reiterated a “buy” rating on shares of Alexion Pharmaceuticals in a research report on Wednesday, September 18th. Finally, Oppenheimer reduced their price target on Alexion Pharmaceuticals from $165.00 to $150.00 in a research report on Thursday, October 24th. One equities research analyst has rated the stock with a sell rating, five have issued a hold rating and sixteen have issued a buy rating to the company’s stock. The stock has an average rating of “Buy” and a consensus price target of $159.00.

Shares of NASDAQ ALXN opened at $109.01 on Tuesday. Alexion Pharmaceuticals has a twelve month low of $92.56 and a twelve month high of $141.86. The company has a current ratio of 3.98, a quick ratio of 3.45 and a debt-to-equity ratio of 0.25. The company has a market capitalization of $24.52 billion, a price-to-earnings ratio of 15.38, a price-to-earnings-growth ratio of 1.05 and a beta of 1.65. The business has a 50 day simple moving average of $102.63 and a 200-day simple moving average of $115.52.

Alexion Pharmaceuticals (NASDAQ:ALXN) last released its quarterly earnings data on Wednesday, October 23rd. The biopharmaceutical company reported $2.79 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $2.47 by $0.32. Alexion Pharmaceuticals had a return on equity of 21.21% and a net margin of 31.05%. The business had revenue of $1.26 billion during the quarter, compared to analyst estimates of $1.24 billion. During the same quarter in the previous year, the firm posted $2.02 EPS. The business’s revenue for the quarter was up 23.0% compared to the same quarter last year. As a group, equities analysts predict that Alexion Pharmaceuticals will post 9.41 earnings per share for the current year.

Several institutional investors and hedge funds have recently bought and sold shares of ALXN. Boltwood Capital Management bought a new stake in shares of Alexion Pharmaceuticals in the 2nd quarter worth $921,000. Private Trust Co. NA raised its stake in shares of Alexion Pharmaceuticals by 3.6% in the 2nd quarter. Private Trust Co. NA now owns 16,054 shares of the biopharmaceutical company’s stock worth $2,102,000 after buying an additional 560 shares in the last quarter. Swedbank raised its stake in shares of Alexion Pharmaceuticals by 95.5% in the 2nd quarter. Swedbank now owns 1,429,397 shares of the biopharmaceutical company’s stock worth $187,222,000 after buying an additional 698,096 shares in the last quarter. DNB Asset Management AS raised its position in shares of Alexion Pharmaceuticals by 33.5% during the second quarter. DNB Asset Management AS now owns 45,269 shares of the biopharmaceutical company’s stock worth $5,929,000 after purchasing an additional 11,362 shares during the period. Finally, Crossmark Global Holdings Inc. raised its position in shares of Alexion Pharmaceuticals by 3.4% during the second quarter. Crossmark Global Holdings Inc. now owns 16,863 shares of the biopharmaceutical company’s stock worth $2,209,000 after purchasing an additional 548 shares during the period. 94.56% of the stock is currently owned by institutional investors.

Alexion Pharmaceuticals Company Profile

Alexion Pharmaceuticals, Inc, a biopharmaceutical company, develops and commercializes various therapeutic products. The company offers ULTOMIRIS (ALXN1210/ravulizumab-cwvz), a monoclonal antibody for the treatment of paroxysmal nocturnal hemoglobinuria (PNH), a genetic blood disorder; and Soliris (eculizumab), a monoclonal antibody for the treatment of PNH, atypical hemolytic uremic syndrome (aHUS), and generalized myasthenia gravis.

Further Reading: What is a stock buyback?

The Fly

Analyst Recommendations for Alexion Pharmaceuticals (NASDAQ:ALXN)

Receive News & Ratings for Alexion Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alexion Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.